The rhPTH (1-34), But not Elcatonin, Increases Bone Anabolic Efficacy in Postmenopausal Women with Osteoporosis

被引:6
|
作者
Zhang, L. [1 ]
Yang, M. [1 ]
Liu, D. [1 ]
Guo, C. [1 ]
Li, L. [1 ]
Yang, G. [1 ]
机构
[1] Chongqing Med Univ, Dept Endocrinol, Affiliated Hosp 2, Chongqing 400010, Peoples R China
基金
中国国家自然科学基金;
关键词
osteoporosis; postmenopausal women; rhPTH; bone turnover markers; PARATHYROID-HORMONE; 1-34; MINERAL DENSITY; BIOCHEMICAL MARKERS; VERTEBRAL FRACTURES; CONTROLLED-TRIAL; CHINESE WOMEN; TERIPARATIDE; CALCITONIN; MASS; AGE;
D O I
10.1055/s-0032-1309009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Intermittent administration of recombinant human PTH [rhPTH (1-34)] exerts an osteoanabolic effect characterized by direct effects on bone formation, increases bone density, and reduces fracture risk. This study was to investigate the anabolic effects of rhPTH(1-34) on postmenopausal osteoporosis in an Asian population and compare the time course and alteration in bone turnover marker (BTM) during rhPTH(1-34) and elcatonin treatment. Methods: 124 women with postmenopausal osteoporosis were enrolled in this prospective, open-label, active-controlled trial. The patients randomized to subcutaneous rhPTH(1-34) (20 ug, once daily) or elcatonin (200U, once week) injections for 12 months. Biochemical markers of bone formation (bone specific alkaline phosphatase [BSAP]), and bone resorption maker (serum C-telopeptide of type I collagen [CTX-1] were measured at baseline and at 0, 6, and 12 months. Results: At 12 months, rhPTH (1-34) significantly increased lumbar spine BMD significantly compared with baseline, whereas elcatonin was ineffective. BSAP levels were gradually increased in almost all rhPTH(1-34)-treated subjects and at the end of the study, the percentage of subjects with BSAP above the postmenopausal reference interval was gradually increased as high as 91.5% at month 12. Opposite trends in percentages for CTX-I was observed in rhPTH(1-34). With rhPTH(1-34), but not elcatonin, there were significant positive correlations between ratio of BSAP and CTX-I and bone mineral density (BMD) (r = 0.318) at the end of month 12. Both treatments were well tolerated and there were no significant differences detected between the 2 groups in the proportion of any adverse events and any serious adverse events. Conclusions: rhPTH (1-34) has more positive effects on bone formation than elcatonin for postmenopausal women with osteoporosis and was proved to be safe and well tolerated. The ratio of BSAP and CTX-I may be a useful indicator for positive bone formation.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [1] Pharmacokinetics of Teriparatide (rhPTH[1-34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
    Satterwhite, Julie
    Heathman, Michael
    Miller, Paul D.
    Marin, Fernando
    Glass, Emmett V.
    Dobnig, Harald
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2010, 87 (06) : 485 - 492
  • [2] Teriparatide [RHPTH (1-34)] treatment reduces the incidence of back pain in postmenopausal women with osteoporosis
    Krege, JH
    Xie, L
    Genant, HK
    [J]. OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S75 - S75
  • [3] A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China
    ZHANG Xiuzhen WANG Bo YANG Jun XUAN Miao SONG Lige LI Hong GUO Xiaohui LU Xiaofeng XUE Qingyun YANG Gangyi JI Qiuhe SHEN Jie LIU Zhimin LI Chengjiang WU Tianfeng TONG Xiaocui and JIA Yuan Department of Endocrinology Tongji Hospital of Tongji University Shanghai China Zhang XZ Wang B Yang J Xuan M Song LG and Li HDepartment of Endocrinology Peking University First Hospital Beijing China Guo XHDepartment of Endocrinology General Hospital of the Chinese Peoples Liberation Army Beijing Military Region Beijing China Lu XFDepartment of Endocrinology Beijing Hospital Beijing China Xue QYDepartment of Endocrinology Second Affiliated Hospital of Chongqing Medical University Chongqing China Yang GYDepartment of Endocrinology Xijing Hospital of Fourth Military Medical University Xian Shaanxi China Ji QHDepartment of Endocrinology Nanfang Hospital of Nanfang Medical University Guangzhou Guangdong China Shen JDepartment of Endocrinology Changzheng Hospital Second Military Medical University Shanghai China Liu ZMDepartment of Endocrinology First Affiliated Hospital of Zhejiang University Hangzhou Zhejiang China Li CJDepartment of Endocrinology Zhejiang Hospital Hangzhou Zheiiang China Wu TF Tong XC and Jia Y
    [J]. 中华医学杂志(英文版), 2009, (24) : 2933 - 2938
  • [4] A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China
    Zhang Xiu-zhen
    Wang Bo
    Yang Jun
    Xuan Miao
    Song Li-ge
    Li Hong
    Guo Xiao-hui
    Lue Xiao-feng
    Xue Qing-yun
    Yang Gang-yi
    Ji Qiu-he
    Shen Jie
    Liu Zhi-min
    Li Cheng-jiang
    Wu Tian-feng
    Tong Xiao-cui
    Jia Yuan
    [J]. CHINESE MEDICAL JOURNAL, 2009, 122 (24) : 2933 - 2938
  • [5] Endogenous intact PTH is suppressed during teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis
    Anastasilakis, Athanasios D.
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    Slavakis, Aristides
    Efstathiadou, Zoe
    Kita, Marina
    Koukoulis, George
    Avramidis, Avraam
    [J]. ENDOCRINE JOURNAL, 2008, 55 (03) : 613 - 616
  • [6] Teriparatide [rhPTH (1-34)], But Not Strontium Ranelate, Demonstrated Bone Anabolic Efficacy in Mature, Osteopenic, Ovariectomized Rats
    Ma, Yanfei L.
    Zeng, Qing Q.
    Porras, Leah L.
    Harvey, Anita
    Moore, Terry L.
    Shelbourn, Timothy L.
    Dalsky, Gail P.
    Wronski, Thomas J.
    Aguirre, J. Ignacio
    Bryant, Henry U.
    Sato, Masahiko
    [J]. ENDOCRINOLOGY, 2011, 152 (05) : 1767 - 1778
  • [7] Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis
    Cosman, Felicia
    Eriksen, Erik Fink
    Recknor, Chris
    Miller, Paul D.
    Guanabens, Nuria
    Kasperk, Christian
    Papanastasiou, Philemon
    Readie, Aimee
    Rao, Hanumantha
    Gasser, Juerg A.
    Bucci-Rechtweg, Christina
    Boonen, Steven
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (03) : 503 - 511
  • [8] Distinctive effects of teriparatide [rhPTH(1-34)] and alendronate on bone turnover and lumbar spine bone density in women with osteoporosis
    McClung, MR
    Miller, PD
    Civitelli, R
    Warren, ML
    Greenspan, SL
    Tamayo, JA
    Donley, DW
    San Martin, J
    [J]. OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S18 - S18
  • [9] Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
    Julie Satterwhite
    Michael Heathman
    Paul D. Miller
    Fernando Marín
    Emmett V. Glass
    Harald Dobnig
    [J]. Calcified Tissue International, 2010, 87 : 485 - 492
  • [10] Effects of elcatonin on bone mass of postmenopausal Chinese women with osteoporosis
    Meng, XW
    Xing, XP
    Xia, WB
    Zhang, ZHW
    Qing, MW
    Yu, W
    Tian, JP
    Zhou, XY
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 : T548 - T548